View Future GrowthPyridam Farma 과거 순이익 실적과거 기준 점검 0/6Pyridam Farma 의 수입은 연평균 -60.6%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 6.5%의 비율로 증가했습니다. 매출은 연평균 42%의 비율로 증가해 왔습니다.핵심 정보-60.59%순이익 성장률-33.94%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률20.38%매출 성장률42.01%자기자본이익률-39.46%순이익률-13.02%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesReported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).공시 • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).공시 • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공시 • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights OfferingNew Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.공시 • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020.매출 및 비용 세부 내역Pyridam Farma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이IDX:PYFA 매출, 비용 및 순이익 (IDR Millions)날짜매출순이익일반관리비연구개발비31 Mar 262,841,499-369,953749,426031 Dec 252,760,422-379,670736,502030 Sep 252,819,223-481,826724,201030 Jun 252,898,895-451,826709,229031 Mar 252,454,633-377,733647,021031 Dec 241,920,812-330,247542,922030 Sep 241,343,423-246,246412,152030 Jun 24795,774-140,158353,719031 Mar 24688,841-116,016319,998031 Dec 23702,068-85,221302,848030 Sep 23684,977-66,728283,380030 Jun 23721,928229,504313,600031 Mar 23707,846260,664294,282031 Dec 22715,425275,241286,433030 Sep 22775,078278,272287,735-57330 Jun 22715,1323,165245,819031 Mar 22685,557-2,877235,143031 Dec 21630,5305,479219,977030 Sep 21488,49621,948175,20757330 Jun 21378,33527,773147,743031 Mar 21315,77728,590133,448031 Dec 20277,39822,104134,340030 Sep 20257,67420,539140,348030 Jun 20247,32113,275131,853031 Mar 20262,33111,823136,496031 Dec 19247,1159,343129,282030 Sep 19249,6449,070133,995030 Jun 19248,9138,505133,832031 Mar 19249,4058,697136,589031 Dec 18250,4468,447137,379030 Sep 18240,1276,303131,081030 Jun 18239,2677,604131,601031 Mar 18235,9447,453128,612031 Dec 17223,0027,127122,523030 Sep 17225,2937,431124,247030 Jun 17210,1353,729118,428031 Mar 17215,8735,508124,424031 Dec 16216,9525,146124,239030 Sep 16217,3935,210125,192030 Jun 16221,9164,383127,340031 Mar 16215,0162,909124,166031 Dec 15217,8443,087127,580030 Sep 15220,0712,953131,8140양질의 수익: PYFA 은(는) 현재 수익성이 없습니다.이익 마진 증가: PYFA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PYFA은 수익성이 없으며 지난 5년 동안 손실이 연평균 60.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PYFA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PYFA은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(7.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PYFA는 현재 수익성이 없으므로 자본 수익률이 음수(-39.46%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/10 10:30종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PT Pyridam Farma Tbk는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Elvira NataliaPT Sinarmas Sekuritas
Reported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).
Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).
Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
공시 • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.
Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).
Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.
Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).
New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
공시 • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.
New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).
New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).
Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공시 • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights Offering
New Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).
Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).
Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.
Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.
Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.
Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.
공시 • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020.